Therapeutic management and outcome of patients with advanced systemic mastocytosis treated with midostaurin: A comprehensive real‐life study in the French national healthcare database
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.3062
Abstract: Advanced Systemic Mastocytosis (Adv‐SM) is rare and has a poor prognosis. Midostaurin (Rydapt®) is one of the few treatments for Adv‐SM in Europe. The study aims were to describe the characteristics of patients treated with… read more here.
Keywords: systemic mastocytosis; advanced systemic; treatment; treated midostaurin ... See more keywords